[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-349999-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-349999-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","immunogenomic-signatures-defining-the-molecular-subtypes-of-head-and-neck-cancer","Immunogenomic signatures defining the molecular subtypes of head and neck cancer","","Immunogenomic signatures are used to define molecular subtypes and improve prognosis prediction in head and neck squamous cell carcinoma (HNSC). The study analyzes transcriptome data from TCGA and GEO together with immune gene data from ImmPort. Cox-LASSO screening identifies nine immune-related gene signatures, followed by risk-score stratification and comparative analyses. Survival, differential expression, GSEA, GO, KEGG, ssGSEA, CIBERSORT, and drug-sensitivity evaluations distinguish high- vs low-risk cohorts and support the construction of a nomogram prediction model.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/immunogenomic-signatures-defining-the-molecular-subtypes-of-head-and-neck-cancer/349999/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/immunogenomic-signatures-defining-the-molecular-subtypes-of-head-and-neck-cancer/349999.png","ImageObject",300,407,{"name":42,"@type":43},"Rhys","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main goal of the study in HNSC?","Question",{"text":63,"@type":64},"To identify immune-related gene signatures for predicting the prognosis of head and neck squamous cell carcinoma (HNSC).","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which data sources are used to derive the immune-related gene signatures?",{"text":68,"@type":64},"Transcriptome data from TCGA and GEO and immune gene data from ImmPort are examined together.",{"name":70,"@type":61,"acceptedAnswer":71},"How are patients stratified and what key results are reported?",{"text":72,"@type":64},"Patients are classified into high- and low-risk cohorts using Cox-LASSO-derived risk scores; high-risk patients show lower immune scores and survival rates, while low-risk patients show higher immune scores and better outcomes.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},349999,1790133080,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},687207024643,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Gao et al. Discover Oncology (2026) 17:456 [https://doi.org/10.1007/s12672-026-04518-y](https://doi.org/10.1007/s12672-026-04518-y)  \nDiscover Oncology  \nANALYSIS Open Access  \nImmunogenomic signatures defining the  molecular subtypes of head and neck cancer  \nLiangbin Gao1†, Bin Wang2†, Jiamin Wang1, Yu Chen1, Ning Li 1, Wei An1,3*† and Zhilin Li2*†  \n\n| †Liangbin Gao and Bin Wang have contributed equally to this work and share first authorship. |\n| --- |\n| †Zhilin Li and Wei An have contributed equally to this work and share corresponding authorship. |\n\n*Correspondence: Wei An [anwei_vip@126.com](anwei_vip@126.com)[ ](anwei_vip@126.com)Zhilin Li [20647613@qq.com](20647613@qq.com)  \nFull list of author information is available at the end of the article  \nAbstract  \nThe immune system is crucial in the development and advancement of cancerous tumors, particularly in head and neck squamous cell carcinoma (HNSC) . This study aimed to identify immune-related gene signatures (IRGs) for predicting the prognosis of HNSC. Transcriptome data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO), in addition to immune gene data from ImmPort, were examined. Using Cox-LASSO screening, nine IRGs were identified, and patients were classified into high-and low-risk cohorts based on risk scores. Differential expression, survival analysis, Gene Set Enrichment Analysis (GSEA), Gene Ontology (GO),  \nKyoto Encyclopedia of Genes and Genomes (KEGG), single-sample GSEA (ssGSEA), CIBERSORT, and drug sensitivity analyses were performed between the cohorts. The high-risk cohorts exhibited lower immune scores and survival rates, while the lowrisk cohorts exhibited higher immune scores and better outcomes. Cox regression identified CD19, CD79A, CTLA4, ICOS, and LAT as protective genes and CHGB, DKK1, PDGFA, and PTX3 as risk genes. Based on these nine genes, we established a nomogram prediction model to further assess patient prognosis. These findings highlight the prognostic value of IRGs in HNSC, offering the potential for personalized treatment strategies based on immune risk profiles.  \nKeywords Head and neck squamous cell carcinoma, prognosis prediction, Risk stratification, Immune-related genes, Nomogram model  \n1 Introduction  \nHead and neck cancers encompass malignancies arising in the oral cavity, pharynx, larynx, nasopharynx, thyroid, and salivary glands, contributing significantly to global morbidity and mortality. According to 2022 global cancer statistics, thyroid cancer ranks eighth worldwide in incidence, with a mortality rate of 0.5%. Oral cancer ranks 16th with a mortality rate of 1.9%, while laryngeal and nasopharyngeal cancers rank 19th and 23rd, with mortality rates of 1.1% and 0.8%, respectively [1]. The 5-year survival rate for patients with head and neck squamous cell carcinoma (HNSC) is approximately 40%~50%[2], primarily due to local recurrence or distant metastasis observed in 80%~90% of patients with advanced-stage disease. Conventional treatments, including  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy ","cbCaiiutaB4hK5yS","https://ap.wps.com/l/cbCaiiutaB4hK5yS","pdf",2383129,17,"English","# Abstract\n# Keywords\n# 1 Introduction","[{\"question\":\"What is the main goal of the study in HNSC?\",\"answer\":\"To identify immune-related gene signatures for predicting the prognosis of head and neck squamous cell carcinoma (HNSC).\"},{\"question\":\"Which data sources are used to derive the immune-related gene signatures?\",\"answer\":\"Transcriptome data from TCGA and GEO and immune gene data from ImmPort are examined together.\"},{\"question\":\"How are patients stratified and what key results are reported?\",\"answer\":\"Patients are classified into high- and low-risk cohorts using Cox-LASSO-derived risk scores; high-risk patients show lower immune scores and survival rates, while low-risk patients show higher immune scores and better outcomes.\"}]","Immunogenomic signatures defining the molecular subtypes of head and neck cancer | PDF",1790086668,43,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/04f2f7b78cd892cb0bf57f4d3d7e52f5.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/21b3d1f278a8c3e07c25337625fba925.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/08d30fb52898ff5e05676524e8ea31bc.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5ecf2ed439a23a7d770c95362bc0fd60.webp",980,1306]